Comments
Loading...

Globus Medical Analyst Ratings

GMEDNYSE
Logo brought to you by Benzinga Data
$60.20
At close: Jun 12 EDT
$60.20
0.000.00%
Pre-Market: 4:00 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$115.00
Lowest Price Target1
$68.00
Consensus Price Target1
$88.43

Globus Medical Analyst Ratings and Price Targets | NYSE:GMED | Benzinga

Globus Medical Inc has a consensus price target of $88.43 based on the ratings of 18 analysts. The high is $115 issued by Roth MKM on December 17, 2024. The low is $68 issued by Truist Securities on May 12, 2025. The 3 most-recent analyst ratings were released by Truist Securities, Piper Sandler, and Truist Securities on May 12, 2025, May 9, 2025, and April 11, 2025, respectively. With an average price target of $76 between Truist Securities, Piper Sandler, and Truist Securities, there's an implied 26.25% upside for Globus Medical Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
3
1
Feb
0
0
0
0
Mar
0
0
0
0
Apr
1
2
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Truist Securities
Piper Sandler
Barclays
Stifel
Wells Fargo

1calculated from analyst ratings

Analyst Ratings for Globus Medical

Buy NowGet Alert
05/27/2025Buy NowJMP Securities
David Turkaly52%
ReiteratesMarket Perform → Market PerformGet Alert
05/27/2025Buy NowBTIG
Ryan Zimmerman70%
DowngradeBuy → NeutralGet Alert
05/12/2025Buy Now12.96%Truist Securities
Richard Newitter73%
$80 → $68MaintainsHoldGet Alert
05/09/2025Buy Now32.89%Piper Sandler
Matt O'Brien53%
$100 → $80MaintainsOverweightGet Alert
04/11/2025Buy Now32.89%Truist Securities
Richard Newitter73%
$82 → $80MaintainsHoldGet Alert
03/18/2025Buy Now36.21%Truist Securities
Richard Newitter73%
$90 → $82MaintainsHoldGet Alert
03/18/2025Buy NowNeedham
David Saxon56%
ReiteratesHold → HoldGet Alert
02/24/2025Buy NowCitizens Capital Markets
David Turkaly52%
ReiteratesMarket Perform → Market PerformGet Alert
02/24/2025Buy Now71.1%Barclays
Matt Miksic66%
$100 → $103MaintainsOverweightGet Alert
02/21/2025Buy Now56.15%Stifel
Mathew Blackman63%
$92 → $94MaintainsBuyGet Alert
02/21/2025Buy Now54.49%Wells Fargo
Vik Chopra44%
$95 → $93MaintainsOverweightGet Alert
02/21/2025Buy NowNeedham
David Saxon56%
ReiteratesHold → HoldGet Alert
02/06/2025Buy NowNeedham
David Saxon56%
ReiteratesHold → HoldGet Alert
01/10/2025Buy Now67.77%Canaccord Genuity
William Plovanic60%
$92 → $101MaintainsBuyGet Alert
01/09/2025Buy Now61.13%B of A Securities
Craig Bijou77%
$80 → $97UpgradeUnderperform → NeutralGet Alert
01/09/2025Buy NowNeedham
David Saxon56%
ReiteratesHold → HoldGet Alert
12/18/2024Buy Now49.5%Truist Securities
Richard Newitter73%
$85 → $90MaintainsHoldGet Alert
12/17/2024Buy Now91.03%Roth MKM
Jason Wittes54%
$100 → $115MaintainsBuyGet Alert
12/12/2024Buy Now51.16%BTIG
Ryan Zimmerman70%
$87 → $91MaintainsBuyGet Alert
12/11/2024Buy Now57.81%Wells Fargo
Vik Chopra44%
$88 → $95MaintainsOverweightGet Alert
12/09/2024Buy Now52.82%Canaccord Genuity
William Plovanic60%
$85 → $92MaintainsBuyGet Alert
12/02/2024Buy Now66.11%Morgan Stanley
Drew Ranieri46%
$83 → $100UpgradeEqual-Weight → OverweightGet Alert
11/11/2024Buy Now37.87%Morgan Stanley
Drew Ranieri46%
$74 → $83MaintainsEqual-WeightGet Alert
11/07/2024Buy Now66.11%Barclays
Matt Miksic66%
$93 → $100MaintainsOverweightGet Alert
11/07/2024Buy NowNeedham
David Saxon56%
Reiterates → HoldGet Alert
11/06/2024Buy Now52.82%Stifel
Mathew Blackman63%
$80 → $92MaintainsBuyGet Alert
11/06/2024Buy Now41.2%Canaccord Genuity
William Plovanic60%
$79 → $85MaintainsBuyGet Alert
11/06/2024Buy Now66.11%Roth MKM
Jason Wittes54%
$100 → $100ReiteratesBuy → BuyGet Alert
11/06/2024Buy Now52.82%RBC Capital
Shagun Singh57%
$80 → $92MaintainsOutperformGet Alert
11/06/2024Buy Now46.18%Wells Fargo
Vik Chopra44%
$78 → $88MaintainsOverweightGet Alert
11/06/2024Buy Now66.11%Piper Sandler
Matt O'Brien53%
$80 → $100MaintainsOverweightGet Alert
11/06/2024Buy Now32.89%B of A Securities
Craig Bijou77%
$55 → $80MaintainsUnderperformGet Alert
11/06/2024Buy NowNeedham
David Saxon56%
Reiterates → HoldGet Alert
10/14/2024Buy Now29.57%BTIG
Ryan Zimmerman70%
$77 → $78MaintainsBuyGet Alert
10/08/2024Buy Now32.89%RBC Capital
Shagun Singh57%
$78 → $80MaintainsOutperformGet Alert
08/28/2024Buy Now27.91%BTIG
Ryan Zimmerman70%
$75 → $77MaintainsBuyGet Alert
08/08/2024Buy Now54.49%Barclays
Matt Miksic66%
$85 → $93MaintainsOverweightGet Alert
08/07/2024Buy Now29.57%RBC Capital
Shagun Singh57%
$76 → $78MaintainsOutperformGet Alert
08/07/2024Buy Now31.23%Truist Securities
Richard Newitter73%
$78 → $79MaintainsHoldGet Alert
08/07/2024Buy Now29.57%Wells Fargo
Vik Chopra44%
$60 → $78UpgradeEqual-Weight → OverweightGet Alert
08/07/2024Buy NowNeedham
David Saxon56%
Reiterates → HoldGet Alert
07/16/2024Buy Now29.57%Truist Securities
Richard Newitter73%
$63 → $78MaintainsHoldGet Alert
07/15/2024Buy Now24.58%BTIG
Ryan Zimmerman70%
$72 → $75MaintainsBuyGet Alert
07/15/2024Buy Now17.94%Morgan Stanley
Drew Ranieri46%
$67 → $71MaintainsEqual-WeightGet Alert
05/29/2024Buy Now19.6%BTIG
Ryan Zimmerman70%
$63 → $72MaintainsBuyGet Alert
05/20/2024Buy Now32.89%Piper Sandler
Matt O'Brien53%
$60 → $80UpgradeNeutral → OverweightGet Alert
05/09/2024Buy Now41.2%Barclays
Matt Miksic66%
$83 → $85MaintainsOverweightGet Alert
05/08/2024Buy Now4.65%BTIG
Ryan Zimmerman70%
$60 → $63MaintainsBuyGet Alert
05/08/2024Buy Now-0.33%Piper Sandler
Matt O'Brien53%
$55 → $60MaintainsNeutralGet Alert
05/08/2024Buy Now16.28%Stifel
Mathew Blackman63%
$64 → $70MaintainsBuyGet Alert
05/08/2024Buy NowNeedham
David Saxon56%
Reiterates → HoldGet Alert
03/18/2024Buy Now-0.33%BTIG
Ryan Zimmerman70%
→ $60UpgradeNeutral → BuyGet Alert
02/21/2024Buy Now31.23%Canaccord Genuity
Caitlin Cronin42%
→ $79ReiteratesBuy → BuyGet Alert
02/21/2024Buy Now-0.33%Truist Securities
Richard Newitter73%
$58 → $60MaintainsHoldGet Alert
01/11/2024Buy Now16.28%RBC Capital
Shagun Singh57%
$70 → $70ReiteratesOutperform → OutperformGet Alert
12/22/2023Buy Now-3.65%Truist Securities
Richard Newitter73%
$53 → $58MaintainsHoldGet Alert
12/20/2023Buy Now17.94%Canaccord Genuity
Kyle Rose68%
$67 → $71MaintainsBuyGet Alert
11/14/2023Buy Now-11.96%Morgan Stanley
Drew Ranieri46%
$60 → $53MaintainsEqual-WeightGet Alert
11/08/2023Buy Now-11.96%Truist Securities
Richard Newitter73%
$58 → $53MaintainsHoldGet Alert
10/20/2023Buy Now24.58%Roth MKM
Jason Wittes54%
→ $75Initiates → BuyGet Alert
10/12/2023Buy Now42.86%Barclays
Matt Miksic66%
$77 → $86MaintainsOverweightGet Alert
09/19/2023Buy Now1.33%Stifel
Mathew Blackman63%
→ $61UpgradeHold → BuyGet Alert
09/15/2023Buy Now-3.65%Wells Fargo
Vik Chopra44%
$63 → $58MaintainsEqual-WeightGet Alert
09/05/2023Buy Now7.97%Truist Securities
Richard Newitter73%
→ $65ReiteratesHold → HoldGet Alert
08/07/2023Buy Now7.97%Truist Securities
Richard Newitter73%
$68 → $65MaintainsHoldGet Alert
08/07/2023Buy Now27.91%Barclays
Matt Miksic66%
$75 → $77MaintainsOverweightGet Alert
08/04/2023Buy Now4.65%Wells Fargo
Vik Chopra44%
$61 → $63MaintainsEqual-WeightGet Alert
07/19/2023Buy Now12.96%Truist Securities
Richard Newitter73%
$64 → $68MaintainsHoldGet Alert
05/31/2023Buy Now-0.33%Morgan Stanley
Drew Ranieri46%
$64 → $60MaintainsEqual-WeightGet Alert
05/24/2023Buy NowJMP Securities
David Turkaly52%
Reiterates → Market PerformGet Alert
05/05/2023Buy Now6.31%Truist Securities
Richard Newitter73%
$66 → $64MaintainsHoldGet Alert
03/30/2023Buy Now11.3%Canaccord Genuity
Kyle Rose68%
→ $67UpgradeHold → BuyGet Alert
03/28/2023Buy Now11.3%Canaccord Genuity
Kyle Rose68%
→ $67Reiterates → HoldGet Alert
02/22/2023Buy Now6.31%Morgan Stanley
Drew Ranieri46%
$78 → $64MaintainsEqual-WeightGet Alert
02/22/2023Buy Now11.3%Canaccord Genuity
Kyle Rose68%
$75 → $67MaintainsHoldGet Alert
02/22/2023Buy Now1.33%Wells Fargo
Vik Chopra44%
$67 → $61MaintainsEqual-WeightGet Alert
02/13/2023Buy Now4.65%B of A Securities
Craig Bijou77%
$83 → $63DowngradeBuy → UnderperformGet Alert
02/10/2023Buy Now11.3%Wells Fargo
Vik Chopra44%
$82 → $67DowngradeOverweight → Equal-WeightGet Alert
02/10/2023Buy Now16.28%Truist Securities
Richard Newitter73%
→ $70DowngradeBuy → HoldGet Alert
02/10/2023Buy Now16.28%Loop Capital
Jason Wittes54%
$90 → $70DowngradeBuy → HoldGet Alert
02/10/2023Buy NowNeedham
David Saxon56%
DowngradeBuy → HoldGet Alert
02/10/2023Buy NowBTIG
Ryan Zimmerman70%
DowngradeBuy → NeutralGet Alert
02/09/2023Buy NowPiper Sandler
Matt O'Brien53%
DowngradeOverweight → NeutralGet Alert
01/06/2023Buy Now29.57%Morgan Stanley
Drew Ranieri46%
$68 → $78MaintainsEqual-WeightGet Alert
12/20/2022Buy Now41.2%Truist Securities
Richard Newitter73%
$74 → $85MaintainsBuyGet Alert
12/12/2022Buy Now36.21%Wells Fargo
Vik Chopra44%
$74 → $82MaintainsOverweightGet Alert
11/09/2022Buy Now12.96%Morgan Stanley
Drew Ranieri46%
$66 → $68MaintainsEqual-WeightGet Alert
10/18/2022Buy Now14.62%Barclays
Matt Miksic66%
→ $69Initiates → OverweightGet Alert
10/12/2022Buy Now24.58%Jefferies
Matthew Taylor69%
→ $75Initiates → BuyGet Alert
10/11/2022Buy Now9.63%Morgan Stanley
Drew Ranieri46%
$62 → $66MaintainsEqual-WeightGet Alert
08/05/2022Buy Now24.58%Piper Sandler
Matt O'Brien53%
$80 → $75MaintainsOverweightGet Alert
07/20/2022Buy Now17.94%Truist Securities
Richard Newitter73%
$76 → $71MaintainsBuyGet Alert
07/15/2022Buy Now2.99%Morgan Stanley
Drew Ranieri46%
$68 → $62MaintainsEqual-WeightGet Alert

FAQ

Q

What is the target price for Globus Medical (GMED) stock?

A

The latest price target for Globus Medical (NYSE:GMED) was reported by JMP Securities on May 27, 2025. The analyst firm set a price target for $0.00 expecting GMED to fall to within 12 months (a possible -100.00% downside). 44 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Globus Medical (GMED)?

A

The latest analyst rating for Globus Medical (NYSE:GMED) was provided by JMP Securities, and Globus Medical reiterated their market perform rating.

Q

When was the last upgrade for Globus Medical (GMED)?

A

The last upgrade for Globus Medical Inc happened on January 9, 2025 when B of A Securities raised their price target to $97. B of A Securities previously had an underperform for Globus Medical Inc.

Q

When was the last downgrade for Globus Medical (GMED)?

A

The last downgrade for Globus Medical Inc happened on May 27, 2025 when BTIG changed their price target from N/A to N/A for Globus Medical Inc.

Q

When is the next analyst rating going to be posted or updated for Globus Medical (GMED)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Globus Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Globus Medical was filed on May 27, 2025 so you should expect the next rating to be made available sometime around May 27, 2026.

Q

Is the Analyst Rating Globus Medical (GMED) correct?

A

While ratings are subjective and will change, the latest Globus Medical (GMED) rating was a reiterated with a price target of $0.00 to $0.00. The current price Globus Medical (GMED) is trading at is $60.20, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch